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Abstract
Purpose: Using radiobiological modelling to estimate normal tissue toxicity, this study investigates the effects of
dose escalation for concurrent chemoradiation therapy (CRT) in lower third oesophageal tumours on the stomach.
Methods and materials: 10 patients with lower third oesophageal cancer were selected from the SCOPE 1
database (ISCRT47718479) with a mean planning target volume (PTV) of 348 cm3. The original 3D conformal plans
(50Gy3D) were compared to newly created RapidArc plans of 50GyRA and 60GyRA, the latter using a simultaneous
integrated boost (SIB) technique using a boost volume, PTV2. Dose-volume metrics and estimates of normal tissue
complication probability (NTCP) were compared.
Results: There was a significant increase in NTCP of the stomach wall when moving from the 50GyRA to the 60GyRA
plans (11–17 %, Wilcoxon signed rank test, p = 0.01). There was a strong correlation between the NTCP values of
the stomach wall and the volume of the stomach wall/PTV 1 and stomach wall/PTV2 overlap structures (R = 0.80
and R = 0.82 respectively) for the 60GyRA plans.
Conclusion: Radiobiological modelling suggests that increasing the prescribed dose to 60Gy may be associated
with a significantly increased risk of toxicity to the stomach. It is recommended that stomach toxicity be closely
monitored when treating patients with lower third oesophageal tumours with 60Gy.
Introduction
The incidence of lower third oesophagus tumours are
increasing in most Western populations [1] and it is
becoming increasingly clear that chemo-radiotherapy
(CRT) is now a valid alternative to surgical resection in
the treatment of both oesophageal and gastroesophageal
junction (GEJ) cancer [2] & [3]. It has been shown that a
combined approach results in a significantly higher over-
all survival rate compared to either chemotherapy or
radiotherapy alone [4] & [5]. However, local in-field re-
currence is still the main reason of treatment failure [6]
following definitive CRT, with >75 % of these occurring
within the gross tumour volume (GTV) when the stand-
ard radiation dose of ≈ 50Gy is delivered. Indeed, local
recurrence also contributes towards a worse prognosis
in GEJ carcinoma [3].
In theory, a higher radiation dose delivered to the
tumour should result in higher local control rate. How-
ever it is only with the recent technological advances in
radiotherapy (RT) planning and delivery that the ability
to deliver increased dose to the tumour whilst minimis-
ing dose to normal, healthy tissue and organs at risk
(OAR) is becoming possible [7]. Increased tumour con-
trol probability (TCP) should therefore be achievable by
increasing the standard dose prescription beyond ≈
50Gy. A retrospective study by Zhang et al. [8] found
that there was significantly higher overall survival in
their patient cohort if the patient was treated in a high
dose group (>51Gy) or a low dose group (<51Gy), whilst
Geh et al. found there was a dose–response relationship
between increasing prescribed radiotherapy dose and
pathological complete response [9]. Bedford et al. [10] also
found that conformal techniques offered the potential of a
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5–10Gy increase in dose delivered to the GTV up to 60Gy
with acceptable increases in toxicity.
The organs most at risk when planning oesophageal
radiotherapy treatment, and for which the most strin-
gent dose constraints are usually applied are the heart,
lungs and spinal cord. Oesophageal cancer cases will
therefore be planned according to a combination of the
achievable dose coverage of the planning treatment vol-
ume (PTV) and the meeting of dose constraints for
these organs. The SCOPE 1 study has shown low rates
of acute and late toxicity with CRT using 4 cycles of cis-
platin and capecitabine, with cycles three and four given
concurrently with 50 Gy in 25 fractions of radiotherapy
[11]. However, the 24 week failure free survival was sig-
nificantly better in the CRT only arm than the CRT plus
cetuximab arm (76 · 9 % (90 % confidence interval 69 ·
7–83 · 0) vs 66 · 4 %, (58 · 6–73 · 6)) and cetuximab will
therefore not be carried forward in future clinical trials.
Work by this group in preparation for the forthcoming
SCOPE 2 trial [12] has shown that dose escalation to
62.5Gy in mid oesophageal patients is feasible, with the
additional dose able to be delivered without exceeding
the OAR dose constraints in 75 % of patients. However,
dose escalation has not yet been studied in lower
oesophageal cancers, when the added proximity of the
relatively radiosensitive stomach provides an added plan-
ning challenge [13]. With the role of radiotherapy dose
escalation identified as a research priority [14] for im-
proving outcomes, it is important to quantify the in-
creased risk that this may pose in sites such as the lower
oesophagus where clinical evidence for dose-toxicity cor-
relation for adjacent organs (such as stomach) is lacking.
This planning study therefore aims to investigate the
feasibility of lower oesophageal dose escalation with a
focus on toxicity to the stomach.
Methods and materials
10 patients with tumours in the lower region (centre of
tumour at 32–40 cm from back of teeth measured via
Endoscopic ultrasound (EUS)) were selected at random
from both arms of the SCOPE 1 database and their clas-
sification as lower region tumours confirmed visually.
SCOPE1 has been ethically approved by the Research
Ethics Committee for Wales and has approval from the
Medicines and Health Care Product Regulatory Agency
to be conducted in the UK. The subset had a range of
planning target volumes (PTV1) from 219 to 484 cm3
and a mean volume of 348 cm3, similar to that of the en-
tire SCOPE 1 cohort (mean 327 cm3). The GTVs and
OARs outlined as per the SCOPE protocol were re-used.
PTV 1 is grown by adding 1 cm isotropcially to the
clinical treatment volume (CTV), itself grown by adding
1 cm radially and 2 cm superiorly and inferiorly (along
axis of oesophagus) to the GTV and may include the
stomach mucosa at the inferior limit. For the purpose of
this specific study and the use of the simultaneous inte-
grated boost (SIB) technique for dose escalation, add-
itional structures were also created. A PTV2 (boost
volume) was created for the dose escalated plans by add-
ing an isotropic 0.5 cm margin to the GTV, supported
by a study by Hawkins et al. [15] and reflecting the tech-
nique in the SCOPE 2 trial where margins will not be
adjusted dependent on tumour position [12]. The proto-
col did not address stomach filling or any dose con-
straints for that organ specifically. There were no
constraints or protocol concerning the filling state of the
stomach in the SCOPE 1 trial and therefore for the pa-
tients in this study. The stomach was contoured as (a)
whole organ and (b) stomach wall. The stomach wall
volume was generated by creating a ring like structure
encompassing the outer 5 mm of the whole stomach
outline. This has been shown to provide a satisfactory
approximation of stomach wall thickness [16] & [17]. In
addition, the stomach and stomach wall structures were
divided into the volume that was within PTV1 (Stomach-
In and StomachWall-In) and outside PTV1 (Stomach-Out
and StomachWall-Out). Specific dose constraints were
given for each for the SIB plans (Table 1) based on the
recommendations of the Quantitative Analyses of Normal
Tissue Effects in the Clinic (QUANTEC) paper for dose
volume effects in the stomach and small bowel [18]. An
SIB dose of 60Gy in 25 fractions was considered to be
clinically meaningful and is being taken forward within an
ongoing prospective dose escalation trial (SCOPE 2).
Table 1 Dose constraints for radiotherapy plans
Dose Constraints
Dose-volume constraints
PTV1 (50 Gy) V95% (47.5 Gy) > 95 %
Dmax (0.1 cc) < 107 % (53.5 Gy)
PTV2 (60 Gy) V95% (57 Gy) > 95 %
Dmax (0.1 cc) < 107 % (64.2 Gy)
Lung Mean dose < 20 Gy
V20Gy < 25 %
Heart Mean dose < 25 Gy
V30Gy < 45 %
a
V40Gy < 30 %
b
CordPRV Dmax (0.1 cc) < 40 Gy (45 Gy permitted)
Liver V30Gy < 60 %
Individual Kidneys V20Gy < 25 %
StomachInc Max dose < 60Gy
StomachOutc Max dose < 45Gy
aApplies only to 50GyRA and 60GyRA plans
bApplies only to 50Gy3D plans
cApplies only to 60GyRA plans
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All treatment planning was undertaken in Eclipse ver-
sion 10 (Varian, Palo Alto CA). The original 3D con-
formal plans were imported in DICOM format and the
doses recalculated using the AAA algorithm with a
2.5 mm grid. RapidArc (RA) plans were generated using
2 arcs of 3600, clockwise and counter-clockwise with a
collimator rotation of ±100. The 50Gy 3D conformal
plans (50Gy3D) were then compared to 50Gy RapidArc
plans (50GyRA) and to plans with an additional simul-
taneously integrated boost of 60Gy to PTV2 (60GyRA)
(See Fig. 1). Dose constraints are listed in Table 1 and
additional dose-volume metrics were calculated for each
structure (Table 2). Patient 6 was originally planned
using 50GyRA therefore a 50Gy3D plan was not created
in this case.
Radiobiological modelling of TCP was undertaken
using the parameters derived by Geh et al. [9]. This
multivariate logistics regression model was constructed
using data from 26 pre-operative CRT trials in
oesophageal cancer and was considered a good repre-
sentative of the SCOPE 1 patient cohort. The TCP
modelling was undertaken bin-wise in Microsoft Excel
using and parameters by Geh et al. found in their ori-
ginal paper [9]. Differential dose-volume histograms
(DVH) for each structure were calculated in CERR uti-
lising Matlab scripts developed in-house [19] before
being converted to relative DVHs in Microsoft Excel.
TCP was calculated as:
TCP zð Þ ¼ exp zð Þ
1 þ exp zð Þ
where z = a0 + a1 total RT dose + a2 total RT dose × dose
per fraction + a3 duration + a4 age + a5 5FU dose + a6 cis-
platin dose. The α/β was 4.9Gy.
Normal tissue complication probability (NTCP) mod-
elling was carried out in Eclipse Biological Evaluation
module using the whole heart volume model of
Gagliardi et al. [20] and for the lung using the model pa-
rameters from De Jaeger et al. [21], which predicts a ra-
diation pneumonitis (RP) of grade 2 or higher. NTCP
models for the stomach are limited therefore modelling
was carried out using those judged to be most relevant.
The whole stomach was modelled using parameters de-
rived by Burman et al. [22] with the endpoint being ul-
ceration, whilst the stomach wall parameters were
derived by Feng et al. [23], modelling the probability of
≥3 grade gastric bleeding.
Data were analysed using the SPSS statistics package
version 20.0.0 (IBM), and results are reported as median
(range) values. Both the Z-score and the P-Values were
calculated.
Results
Table 2 reports the dose-volume metrics and the results
of the Wilcoxon signed rank test for all radiotherapy
plans. Adequate target dose coverage was possible for all
Fig. 1 a 50Gy3D plan with GTV, PTV and stomach outline. b 50GyRA plan with GTV, PTV and stomach outline. c 60GyRA plan with GTV, PTV2, PTV
and stomach outline. Outlines: GTV– dashed orange, PTV– dashed red, PTV2– dashed blue, Stomach– dashed green
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patients in all treatment modalities when considering
the coverage of PTV1 (Table 2). 4 patients failed to meet
the minimum coverage of PTV2 with the minimum
coverage being 92.4 %. All OAR dose for the heart and
lung were met for all patients for all treatment plans. 6 pa-
tients failed to meet the Stomach-In constraint and 1
failed to meet the Stomach-Out constraint for the 60GyRA
plans. All other dose constraints in Table 1 were met.
There was a mean decrease 1.0 % (−3.0 %, 0.6 %) in
TCP from the 50Gy3D to the 50GyRA plans, a mean in-
crease of 12.0 % (9.9 %, 13.6 %) in TCP from the 50Gy3D
plans to the 60GyRA plans and a mean increase of
13.0 % (12.4 %, 13.4 %) in TCP from the 50GyRA plans
to the 60GyRA plans. For NTCP there was a mean de-
crease of 3.4 % (−6.3 %, 0 %) for the heart from the
50Gy3D to the 50GyRA plans, a mean decrease of 2.2 %
(−4.9 %, 2.0 %) from the 50Gy3D to the 60GyRA plans
and a mean increase of 1.2 % (0.5 %, 2.0 %) in NTCP for
the heart from the 50GyRA to the 60GyRA plans. For
lung there was a mean increase of 0.4 % (−0.8 %, 2.2 %)
in NTCP from the 50Gy3D to the 50GyRA plans, a mean
increase of 1.0 % (−0.6 %, 3.2 %) from 50Gy3D to
60GyRA, and a mean increase of 0.6 % (0.1 %, 1.2 %)
from the 50GyRA to the 60GyRA plans.
Table 2 Dose volume metrics for all radiotherapy plans
Comparison of dose-volume metrics, TCP and NTCP values
50Gy3D 50GyRA 60GyRA Wilcoxon signed-rank test
Median (range) Median (range) Median (range) 50Gy3D–50GyRA 50Gy3D–60GyRA 50GyRA–60GyRA
PTV1
V95% 98.2 (96.0–100) 99.1 (95.2–100) 97.0 (95.0–98.2) Z = 0.53 (p = .57) Z = 1.07 (p = .28) Z = 1.36 (p = .17)
PTV2 (GTV + 0.5 cm)
V95% 95.1 (92.4–97.4)
TCP (%) Geh 38.7 (37.5–41.1) 37.8 (37.5–38.7) 50.9 (50.7–51.4) Z = 2.11 (p = .04) Z = 2.67 (p = .01) Z = 2.81 (p = .01)
Lung
Mean dose (Gy) 9.8 (6.0–11.1) 10.2 (5.8–14.3) 10.7 (6.4–15.2) Z = 1.78 (p = .07) Z = 2.40 (p = .02) Z = 2.80 (p = .01)
V13Gy (%) 26.8 (20.0–35.9) 32.8 (15.1–51.6) 34.4 (18.0–54.2) Z = 2.19 (p = .03) Z = 2.55 (p = .01) Z = 2.09 (p = .04)
V20Gy (%) 19.7 (12.3–24.3) 11.3 (4.6–17.4) 15.6 (6.5–23.4) Z = 2.55 (p = .01) Z = 1.72 (p = .09) Z = 2.81 (p = .01)
NTCP (%) De Jaeger 5.1 (1.9–6.0) 4.3 (2.8–8.0) 4.7 (3.1–9.0) Z = 1.49 (p = .14) Z = 2.09 (p = .04) Z = 2.80 (p = .01)
Heart
Mean dose (Gy) 26.8 (13.9–31.2) 21.2 (14.6–23.6) 20.2 (16.4–23.2) Z = 1.68 (p = .09) Z = 1.58 (p = .11) Z = 0.15 (p = .88)
V30Gy (%) 55.1 (9.7–67.9) 17.2 (8.2–25.3) 18.7 (10.3–22.6) Z = 2.67 (p = .01) Z = 2.55 (p = .01) Z = 0.87 (p = .39)
V40Gy (%) 16.2 (5.9–24.5) 10.1 (4.5–14.8) 10.6 (5.6–13.6) Z = 2.67 (p = .01) Z = 2.67 (p = .01) Z = 1.58 (p = .11)
NTCP (%) Gagliardi 8.9 (3.1–12.8) 4.9 (2.2–7.3) 6.1 (2.9–7.9) Z = 1.90 (p = .06) Z = 1.38 (p = .17) Z = 2.80 (p = .01)
Stomach
Mean dose (Gy) 29.8 (5.5–44.2) 24.1 (5.4–40.4) 23 (6.5–36.1) Z = 1.17 (p = .24) Z = 0.97 (p = .33) Z = 1.60 (p = .11)
Max dose (Gy) 52.6 (49.6–53.4) 51.9 (42.4–52.9) 60.9 (51.6–61.6) Z = 0.83 (p = .41) Z = 2.61 (p = .01) Z = 2.81 (p = .01)
V45 (cc) 47.3 (7.3–80.4) 32.8 (0–49.8) 34.3 (5.4–25.4) Z = 2.60 (p = .01) Z = 2.50 (p = .01) Z = 0.36 (p = .72)
V50 (cc) 31.5 (0–23.4) 17.7 (0–14.8) 21.4 (2.2–19.2) Z = 2.31 (p = .02) Z = 1.78 (p = .07) Z = 1.27 (p = .20)
StomachIn max dose (Gy) 52.6 (49.6–53.4) 51.9 (42.4–52.9) 60.9 (51.6–61.6) Z = 0.77 (p = .44) Z = 2.61 (p = .01) Z = 2.81 (p = .01)
StomachOut max dose (Gy) 51.4 (49.4–53.1) 44.4 (36.6–43.6) 44.8 (42.3–46.1) Z = 1.76 (p = .07) Z = 1.79 (p = .07) Z = 0.14 (p = .88)
NTCP (%) Burman 0.6 (0–2.5) 0.2 (0–1.3) 0.3 (0–3.4) Z = 2.38 (p = .02) Z = 0.35 (p = .73) Z = 2.03 (p = .04)
Stomach wall
Mean dose (Gy) 29.5 (8.2–42.6) 22.9 (7.9–38.7) 22.4 (9.1–35.0) Z = 0.97 (p = .33) Z = 0.76 (p = .45) Z = 0.87 (p = .39)
Max dose (Gy) 52.6 (49.6–53.4) 51.9 (43.4–52.9) 61 (51.6–61.6) Z = 0.77 (p = .44) Z = 2.55 (p = .01) Z = 2.81 (p = .01)
V45 (cc) 28 (6.2–39.9) 17.9 (0–26.9) 17.9 (5.4–25.4) Z = 2.19 (p = .03) Z = 2.19 (p = .03) Z = 0.46 (p = .65)
V50 (cc) 15.8 (0–23.4) 9.1 (0–14.8) 9.2 (2.2–19.2) Z = 2.31 (p = .02) Z = 1.48 (p = .14) Z = 1.28 (p = .20)
NTCP (%) Feng 17.4 (3.5–24.9) 11.1 (3.6–18.9) 17.5 (3.2–39.4) Z = 1.72 (p = .09) Z = 1.99 (p = .05) Z = 2.70 (p = .01)
Cord PRV
Dmax 0.1 cc (Gy) 36.9 (16.1–41.3) 31.1 (26.2–44.1) 34.9 (28.4–39.6) Z = 0.47 (p = .64) Z = 0.18 (p = .86) Z = 1.67 (p = .10)
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For the stomach and stomach wall the variation in
NTCP between patients was considerable. Patients 1, 2,
6 & 8 all had stomach NTCP values <0.03 % for all treat-
ment plans whilst the largest value was 3.4 % for a pa-
tient planned using the 60GyRA technique. The stomach
wall model, which models a different endpoint, showed
considerably larger absolute values of NTCP, the largest
being 39.4 % for a patient treated with the 60GyRA plan.
Across the whole study, there was a mean decrease in
stomach wall NTCP of 3.1 % (−6.5, 0 %) from the
50Gy3D plans to the 50GyRA plans, a mean increase of
5.9 % (−4.7, 18.7 %) in NTCP from the 50Gy3D to the
60GyRA plans and a mean increase of 8.2 % (−0.4,
21.3 %) in NTCP from the 50GyRA to the 60GyRA plans
(NTCP values see Fig. 2).
When the NTCP modelling is restricted to the volume
outside the boost volume (PTV2), there was in general a
smaller difference between the NTCP values between
plans. In this case there was a mean decrease of 3.4 %
(−7.4 %, 0.3 %) from the 50Gy3D to the 50GyRA plans, a
mean decrease of 0.9 % (−4.7 %, 1.0 %) in NTCP from
the 50Gy3D to the 60GyRA plans, and a mean increase of
2.3 % (−0.4 %, 6.9 %) in NTCP from the 50GyRA to the
60GyRA plans (Fig. 3).
Table 3 shows the Pearson correlation coefficients be-
tween the Stomach and Stomach Wall volumes and as-
sociated dose metrics. It can be seen how the strongest
correlations are between the stomach wall volumes in
each plan and the mean does received by those volumes
(0.63, 0.66 and 0.66 for the 50Gy3D, 50GyRA and 60GyRA
respectively).
Six patients had an overlap between the GTV and
PTV2 and Stomach Wall structure whilst all patients
had an overlap between the PTV1 and Stomach Wall
structures. There was a strong correlation between the
NTCP value and the Stomach Wall structure/PTV1
overlap structure volume for all treatment plans (Pear-
son’s R = 0.80, 0.77 and 0.77 for the 60GyRA, 50GyRA
and 50Gy3D plans respectively). Fig. 4 shows the correl-
ation between NTCP and the Stomach Wall/PTV1 over-
lap structure volume for the 60GyRA plans.
There was also a strong correlation between the NTCP
value and the Stomach Wall/PTV2 overlap structure
volume for the 60GyRA plan (R = 0.82) (Fig. 5).
Discussion
This study has shown that using the SIB technique it is
possible to deliver a dose of 60Gy to the tumour whilst
adhering to all standard OAR dose constraints for lower
oesophagus tumours.
It is acknowledged that the TCP model used in this in-
vestigation does not account for Cetuximab administra-
tion, however Cetuximab will not be administered in the
SCOPE 2 trial at which this study is aimed. A strength
of the TCP model proposed by Geh et al. is that it com-
bines a diverse range of trials, and it was therefore con-
sidered the most appropriate to use here. It has been
shown that there is a small reduction (<1 %) in TCP
when comparing the 50Gy3D plans to the 50GyRA plans.
There was a higher lung mean V13Gy, but reduced
V20Gy, Heart V30 /40Gy, Stomach V45/50 cc and Stom-
ach Wall V45/50 cc. When comparing the 50GyRA to
the 60GyRA plans there was a significant increase in
TCP but also an increase in the mean dose parameter
for the lung (See Table 2). There was a significant in-
crease in mean TCP (≈12) going from the 50Gy3D to the
60GyRA plan. Comparing 50Gy3D and 50GyRA, there was
a statistically significant increase in lung V13Gy, which
can be explained by the low dose wash associated with
RapidArc type treatment plans, however V20Gy reduced
Fig. 2 NTCP for whole stomach wall for 50Gy3D, 50Gy3D and 60GyRA radiotherapy plans
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and mean lung NTCP was reduced from 5.1 % to 4.3 %.
There was a significant decrease in the heart V30/40Gy
values. Although this did not result in a significant de-
crease in NTCP between the two planning methods in
this study, this agrees with results from our previous
work on mid-oesophageal cancer patients [12].
Moving from the 50GyRA to the 60GyRA plans, al-
though the NTCP values for the heart and lung were
lower than those found in our previous study on mid
oesophageal cancer patients as would be expected, there
was still a similar modest increase in heart and lung tox-
icities when using the boost technique [12]. This also
agrees with the recently published study by Roeder et al.
who delivered 60Gy to patients with oesophageal cancer
using a SIB technique and found acceptable acute and
late overall toxicity to the lung and heart [24]. However,
when treating lower oesophageal tumours there is the
added complication of having the stomach adjacent to
the treatment volume. The involvement of the group in
a proposed randomized clinical trial investigating dose
escalation (SCOPE 2) therefore led to this study, which
is the first to specifically investigate the effect of dose
escalation in lower oesophageal tumours on the stomach
using radiobiological modelling. It is acknowledged that
biological modelling and the resulting outcomes are ex-
tremely dependent on the model parameters used as
well as how they are applied. As a result, we used two
models for the stomach and applied them to both to the
structure as a whole and inside and outside the PTV.
The model for the stomach wall by Feng et al. [23] was
found to predict a higher rate of toxicity than that for
the whole stomach, most likely the result of the different
endpoints of gastric bleeding and ulceration being mod-
elled respectively. Max dose constraints of 45Gy and
60Gy were applied to the stomach outside (Stomach-
Out) and inside (Stomach-In) the PTV respectively for
the 60GyRA plans. The NTCP results for the 60GyRA
when modelling the volume outside the PTV were simi-
lar to those of the 50GyRA and 50Gy3D plans (Max
NTCP of 23.0 % and 23.4 % for the 60GyRA and 50Gy3D
plans respectively), suggesting that dose escalation may
not pose any more risk to normal stomach than 3D con-
formal radiotherapy (Fig. 3). However, when considering
the stomach wall structure as a whole it was found that
Fig. 3 NTCP for stomach wall minus PTV2 for 50Gy3D, 50Gy3D and 60GyRA radiotherapy plans
Table 3 Pearson correlation coefficients between stomach, stomach wall volumes and dose metrics
Pearson Coefficient
50Gy3D 50GyRA 60GyRA
Stomach Volume - Stomach Mean Dose 0.35 0.60 0.61
Stomach Volume - Stomach Max Dose −0.19 0.12 0.55
Stomach Volume - Stomach V45 0.16 0.08 −0.02
Stomach Volume - Stomach V50 0.11 0.05 −0.04
Stomach Wall Volume - Stomach Wall Mean Dose 0.63 0.66 0.66
Stomach Wall Volume - Stomach Wall Max Dose −0.12 0.32 0.68
Stomach Wall Volume - Stomach Wall V45 0.23 0.21 0.12
Stomach Wall Volume - Stomach Wall V50 0.38 0.22 0.04
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there was up to 20 % increase in NTCP when using the
dose escalation plan compared to the 50GyRA plan. This
value however could be considered as being the worse
case scenario, as it is acknowledged that stomach move-
ment and filling over the course of treatment may blur
out any dose hot spots. The analysis of any accompany-
ing Cone Beam CT data of these patients would help
quantify this movement however this data was unavail-
able. Any NTCP value is also by nature calculated from
a model that is open to interpretation therefore should
only be used to give an approximate risk. It is fully ac-
knowledged that radiobiological modelling inherently
has limitations that limit its accuracy. Specifically in the
case of this study, there is a lack of both clinical out-
come data and radiobiological models for stomach tox-
icity when prescribing a dose >50Gy. However the
model used was deemed to be the most suitable in this
instance. The application of radiobiological modelling to
partial organ irradiation is also a contentious one that
may affect the results. However the purpose of this study
was not to give definitive values of stomach toxicity, but
to investigate and inform of the potential relative risks
involved in dose escalation of lower esophageous tu-
mours both in a forthcoming trial and in clinical
practice.
We have shown that there is a strong correlation in
NTCP with the volume of overlap between the stomach
wall with both PTV1 and the high dose region PTV2.
When more clinical data is available it may become ap-
parent that safe delivery of the 60Gy SIB is dependent
on this volume of the overlap, which could potentially
be reduced by reducing the treatment margins for
Fig. 4 NTCP vs whole stomach wall/PTV1 overlap structure volume for 60GyRA radiotherapy plans
Fig. 5 NTCP vs whole stomach wall/PTV2 overlap structure volume for 60GyRA radiotherapy plans
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individual patients using techniques such as 4DCT, gat-
ing and breath hold protocols. However it has been re-
ported that the inter-patient motion of oesophageal
tumours is highly variable [25] and that even the use of
4DCT may not even fully account for organ motion in
between fractions [26]. Nakamura et aldiscuss how large
variations in stomach volume may have a detrimental ef-
fect on dose escalation when treating pancreatic cancer,
despite using a breath hold technique [27]. The impact
of variation in gas in the stomach on dose distribution
should also be considered. For example, Kumagai et al.
found that dose conformation to the CTV was degraded
due to bowel gas movement when treating pancreatic can-
cer using carbon ion beams [28] and consequently may
also be applicable when using photon beams. Bouchard
et al. also found that changes in stomach filling resulted in
the boost target being missed when treating GEJ tumours
with IMRT-SIB [29]. A move to reduction in population-
based margins from those used in the SCOPE 1 and
SCOPE 2 trials, rather than on an individual basis, may
therefore increase the risk of failure to control the disease.
The margins used in this investigation were taken from
the SCOPE 2 protocol therefore give an approximation of
results from a forthcoming nationwide trial, taking into
account the inherent errors in radiobiological modelling.
Concerning the impact of stomach filling, as there was
no stomach filling protocol for the SCOPE 1 trial an area
for further work would; be to investigate what impact, if
any, the inclusion of a filling or breath hold protocol
would have on stomach toxicity and dose distribution
when treating lower oesophageal tumours. However this
is beyond the scope of this current work as it would re-
quire either the incorporation of a protocol into a clin-
ical trial made available for analysis or a retrospective
analysis of patients who underwent an appropriate strat-
egy prior to treatment.
An inclusion criteria for the SCOPE 1 trial was that
patients were to have histologically confirmed carcinoma
of the oesophagus with no more than 2 cm of mucosal
tumour extension into the stomach. As this patient
group is likely to be included in the SCOPE 2 trial, this
study’s findings mean it is likely that it be advised in the
radiotherapy protocol that these patients be treated with
caution until the safety of this dose escalation method is
clearly defined within the SCOPE 2 trial.
The results of this study also suggest that the max-
imum prescribed dose achievable for each patient may
be dependent on the volume of the stomach overlap
with the treatment volume. Further work will therefore
include modelling individualised dose prescription.
Conclusion
Radiobiological modelling suggests that increasing the
prescribed dose to 60Gy may be associated with a
significantly increased risk of toxicity to the stomach
within the boost volume. The results of this study also
suggest that the maximum prescribed dose safely achiev-
able for each patient in the future may be dependent on
the volume of the stomach within the treatment volume.
It is recommended that stomach toxicity be closely moni-
tored prospectively when treating patients with lower
oesophageal tumours in the forthcoming SCOPE 2 trial.
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